OBJECTIVES: The Sherlock 3CG^® Tip Confirmation System (TCS) is designed to confirm the correct tip placement of a peripherally inserted central catheter (PICC) by using magnetic real-time tracking and electrocardiographic catheter tip confirmation. The National Institute for Health and Care Excellence (NICE) recommended the adoption of Sherlock 3CG^® TCS based on modelled health economic benefits in the United Kingdom (U.K.). The objective of this study was to develop a United States (U.S.) model for Sherlock 3CG^® TCS and compare these results to the U.K. analyses. METHODS: Sherlock 3CG^® TCS was compared with “blind” beside PICC placement, as well as region-specific PICC placement methods (i.e., fluoroscopy in the U.K. and tip location system (TLS) in the U.S.). Clinical and economic outcomes were assessed per patient over the duration of a successful PICC insertion procedure. All eligible patients with an identifiable P-wave in their ECG rhythm were assumed to switch to Sherlock 3CG^® TCS and did not require confirmatory chest x-rays. PICC placement success rates, as well as region-specific costs for capital, maintenance, nurse training, consumable materials, and chest x-rays were included. Parameters and assumptions were based on the NICE/External Assessment Centre report and published literature when possible. RESULTS: Adoption of Sherlock 3CG^® TCS was predicted to be more or less cost neutral per patient when compared with “blind” bedside in both the U.K. (£9.37) and the U.S. ($18.73). Further, Sherlock 3CG^® TCS was predicted to be cost-saving per patient compared with fluoroscopy in the U.K. (-£106.12) or compared with a TLS in the U.S. (-$18.43). These results were robust to the majority of sensitivity analyses. CONCLUSIONS: This study predicts that Sherlock 3CG^® TCS is an economically favorable strategy from both U.K. and U.S. perspectives and can provide additional patient and healthcare worker benefits. Additional analyses in other regions may help to further substantiate these results.